Erasca, Inc. (ERAS): Price and Financial Metrics
ERAS Price/Volume Stats
| Current price | $2.54 | 52-week high | $3.45 |
| Prev. close | $2.45 | 52-week low | $1.64 |
| Day low | $2.38 | Volume | 2,426,900 |
| Day high | $2.59 | Avg. volume | 1,613,733 |
| 50-day MA | $2.80 | Dividend yield | N/A |
| 200-day MA | $2.54 | Market Cap | 718.13M |
ERAS Stock Price Chart Interactive Chart >
Erasca, Inc. (ERAS) Company Bio
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. Its lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of NSCLC, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. The company was incorporated in 2018 and is headquartered in San Diego, California.
ERAS Price Returns
| 1-mo | -2.31% |
| 3-mo | -12.11% |
| 6-mo | 17.59% |
| 1-year | 20.38% |
| 3-year | -81.78% |
| 5-year | N/A |
| YTD | 19.25% |
| 2023 | -50.58% |
| 2022 | -72.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...